Design Therapeutics is developing DT-216P2, a small-molecule drug candidate for Friedreich's Ataxia (FA) using its proprietary GeneTAC platform targeting repeat-expansion diseases. Their RESTORE-FA trial has produced promising data, enhancing the drug's credibility. The company plans to clarify the drug's regulatory path with the FDA by Q4 2026 and has sufficient funding to continue operations through 2029, supporting optimism about future progress and milestones.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Cardano has introduced native support for BLS12-381 elliptic curve cryptography in its Plutus smart contracts, enabling the verification of thousands of signatures on-chain at a low and predictable cost. This technology compresses multiple signatures...
